GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » 6-Month Share Buyback Ratio

Firebrick Pharma (ASX:FRE) 6-Month Share Buyback Ratio : -7.58% (As of Dec. 2024 )


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Firebrick Pharma's current 6-Month Share Buyback Ratio was -7.58%.


Competitive Comparison of Firebrick Pharma's 6-Month Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Firebrick Pharma's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's 6-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's 6-Month Share Buyback Ratio falls into.


;
;

Firebrick Pharma 6-Month Share Buyback Ratio Calculation

Firebrick Pharma's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2024 ) - Shares Outstanding (EOP) (Dec. 2024 )) / Shares Outstanding (EOP) (Jun. 2024 )
=(195.307 - 210.109) / 195.307
=-7.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Firebrick Pharma  (ASX:FRE) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Firebrick Pharma 6-Month Share Buyback Ratio Related Terms


Firebrick Pharma Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines